Marinus Pharmaceuticals Adds $21M Series C
Marinus Pharmaceuticals Inc., has added $21 million in Series C financing from Domain Associates, RusnanoMedInvest, Canaan Partners, Sofinnova Ventures and Foundation Medical Partners. Branford, Conn.-based Marinus is the developer of the neuroactive steroid Ganaxolone.
7 January 2013•3 mins read
